Factors related to poor adherence in Latvian asthma patients by Smits, Dins et al.
Smits et al. 
Allergy Asthma Clin Immunol           (2020) 16:16  
https://doi.org/10.1186/s13223-020-0414-6
RESEARCH
Factors related to poor adherence in Latvian 
asthma patients
Dins Smits1* , Girts Brigis1, Jana Pavare2, Inga Urtane3, Sandis Kovalovs2 and Noël Christopher Barengo2,4,5
Abstract 
Background: The problem of nonadherence to therapy is a key reason of insufficient asthma control. Evaluating 
the beliefs about asthma medication, cognitive and emotional perceptions may help to identify patients with poor 
adherence to treatment in clinical practice which need additional attention in order to increase the likelihood of them 
taking their asthma medication according to the prescribed treatment protocol. The purpose of this study is to assess 
whether beliefs about asthma medication, cognitive and emotional factors are related to poor treatment adherence 
of asthma medication in a sample of asthma patients in Latvia.
Methods: Study subjects were asthma patients attending outpatient pulmonologist consultations in Latvia during 
September 2013 to December 2015. Beliefs about asthma medicine, cognitive and emotional factors related to 
asthma were determined in a cross-sectional, self-administered survey. The validated Beliefs about Medicines 
Questionnaire (BMQ) and the Brief Illness Perception Questionnaire (brief IPQ) were used. Treatment adherence was 
assessed using 5-item version of the Medication Adherence Reporting Scale (MARS). The total sample size was 352 
patients. Logistic regression models were used to predict poor adherence to asthma treatment. The validity of each 
logistic regression model was assessed by the Hosmer/Lemeshow test. The main outcome measure was self-reported 
adherence to treatment.
Results: The more the patients agreed with the statement “My future health depends on my asthma medication” the 
lower the possibility of poor adherence to asthma treatment (OR 0.42; 95% CI 0.24–0.74). The more concerned the 
patients were in regard to long-term effects of their medication (OR 2; 95% CI 1.22–3.27), the higher the probability of 
poor treatment adherence.
Conclusions: Screening asthma patients using the BMQ may help to identify those to benefit from interventions 
targeting their concerns and medication beliefs in order to improve adherence to asthma medication.
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Background
The problem of non-adherence to the therapy is one of 
the main reasons of insufficient asthma control [1–3]. 
Studies assessing treatment plans in asthma patients 
have revealed that adherence to medication range 
between 30 and 70% [4–6]. Several factors related to 
the patient, to the disease, treatment or physician–
patient relationship have been identified to be related 
with adherence in asthma and other diseases [7–12]. 
According to the self-regulation theory, both illness 
perception and medication beliefs are associated with 
medication adherence [13, 14]. Particularly beliefs 
about illness, the necessity and the concerns (side 
effects and addition) of the pharmaceutical treatment 
have been identified to be the two most important 
elements in the proposed theory [13–16]. Other 
factors that impact adherence to treatment are cost 
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of therapy, perceived efficacy of medicines, complex 
dosing regimens. Cost of treatment might be of 
particular concern for asthma patients in Latvia since 
the reimbursement level for asthma medication is 75% 
of the total medication cost.
Evaluating the beliefs about asthma medication, 
cognitive and emotional perceptions may help to 
identify patients with poor adherence to treatment in 
clinical practice. That would guide additional attention 
helping to increase the likelihood of taking asthma 
medication appropriately. However, only limited 
information is available on treatment adherence 
in Latvian asthma patients. Furthermore, evidence 
identifying medication beliefs, cognitive or emotional 
factors associated with asthma medication adherence 
among Latvian population is currently not available.
Aim of the study
The aim of this study was to investigate whether beliefs 
about asthma medication, cognitive and emotional 
factors are related to poor adherence of asthma 
medication in a sample of Latvian asthma patients.
Method
Study population
The study population of this cross-sectional patient 
survey consisted of asthma patients attending 
outpatient pulmonologist consultations in Latvia. 
The data were gathered during a period of 28  months 
from September 2013 to December 2015. In a first 
step, a list of all pulmonologists from the database of 
the National Health Service of the medical doctors 
that have contractual rights to prescribe reimbursed 
medicines was acquired. Then, pulmonologist practices 
in medical centres and hospitals in Riga and in bigger 
towns of Latvia were selected and invited to join 
the study. 15 of these practices agreed to participate 
(convenience sample). These 15 medical centres employ 
66 pulmonologists that is 51% of all 129 pulmonologists 
in Latvia that have a contract with NHS. We 
assumed these 15 practices to be representative of all 
pulmonologist practices in Latvia. Each pulmonologist 
was advised to invite their patients to join the survey. 
Patients’ age group were 15  years and older. Patients 
using controller medication–inhaled glucocorticoids in 
monotherapy or in combination with long acting beta 2 
mimetic medicines for at least 12  months prior to the 
study were included. The sample size was calculated to 
detect a prevalence of poor asthma control of 50% with 
a margin of error of 5%, and a power of 95%. The total 
sample size needed was 352 people.
Assessment of main variables
A self-administered questionnaire was used to assess 
socio-demographic and economic factors such as age, 
education, income and sex.
Adherence to asthma medication was assessed using 
5-item version of the Medication Adherence Reporting 
Scale (MARS). MARS is a validated questionnaire 
that has shown to have good internal, construct and 
criterion validity, including correlations with objective 
measures of adherence (electronic monitoring and 
pharmacy dispensing data) [6, 17]. The short version of 
the MARS is a five-item self-report scale for assessment 
of adherent behavior that includes assessment of:
• unintentional non-adherent behavior
 “I forgot to take them”, (item 1) and
• intentional non-adherent behavior
 “I alter the dose”, (item 2).
 “I stop taking them for a while”, (item 3).
 “I decide to miss out a dose”, (item 4).
 “I take less than instructed”, (item 5).
Each item was answered using a five-graded response 
scale, ranging from very often (1) to never (5). Low 
scores indicate low levels of adherent behavior [18].
Medication beliefs were assessed using the five items 
of greatest relevance to asthma medication adapted 
from the BMQ, a validated tool across many disease 
conditions [19]. The specific–necessity scale contains 
5 items that assess patients’ beliefs about specific 
necessity to take prescribed chronic medications. All 
three questions assessing patients’ beliefs about specific 
necessity to take prescribed chronic medications or 
concerns were selected from the original BMQ. All 
belief items had Likert scale responses.
The Brief Illness Perception Questionnaire (brief IPQ) 
was used to obtain information on illness perception of 
the study participants. The Brief IPQ consists of eight 
items and a causal question [20, 21]. All of the items 
except the causal question are rated using a 0-to-10 
response scale. Five of the items assess cognitive illness 
representations: consequences (item 1), timeline (item 
2), personal control (item 3), treatment control (item 4), 
and identity (item 5). Two of the items assess emotional 
representations: concern (item 6) and emotions (item 
8). One item assesses illness comprehensibility (item 7). 
Assessment of the causal representation is by an open-
ended response, which asks patients to list the three 
most important causal factors in their illness (item 9).
Statistical analysis
The Statistical Package for the Social Sciences (SPSS) 
IBM 21.0 was used to analyse the data. Means, standard 
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deviations, and frequencies are presented to describe the 
characteristics of the study sample. A cutoff point of > 6 
for MARS-5 was used to define poor medical adherence.
The answers of the BMQ were dichotomized into (i) “I 
agree/I completely agree” and (ii) “Not sure/I disagree/I 
completely disagree”. The logistic regression analyses 
were first conducted for each variable alone. In the 
multivariate logistic analysis, the outcome variable was 
controlled for age, income and educational level. The 
odds ratio and respective 95% confidence interval are 
presented for all models. The validity of each logistic 
regression model was assessed by the Hosmer/Lemeshow 
test.
Results
The baseline characteristics of the study population are 
presented in Table 1.
The majority of the patients had vocational education 
and were earning at least 300 euros per month. Two out 
of three patients were using glucocorticoids and one-
third a combination therapy consisting of glucocorticoids 
and a beta 2 mimetic drug. The prevalence of poor 
treatment adherence was 58.1% in men and 68.7% in 
women.
We observed that monotherapy with corticosteroids 
reduced the odds of poor treatment adherence whereas 
fixed-dose combination medications containing a 
corticosteroid and a beta 2 mimetic increased the odds of 
poor treatment adherence.
None of the socio-demographic or socio-economic 
factors were predictors of poor treatment adherence 
(Table  2). Vocational level of education seemed to 
increase the odds to have poor treatment adherence.
Table  3 shows the odds ratio of the association 
between cognitive and emotional illness indicators with 
poor treatment adherence. Apparently, none of these 
indicators were able to predict poor treatment adherence 
in Latvian asthma patients.
Several beliefs about medication were identified 
as predictors of poor treatment adherence (Table  4). 
Asthma patients who were convinced that their future 
health depended on the asthma treatment were less 
likely to have poor treatment adherence (OR 0.42: 95% 
CI 0.24–0.74). In case the patient was concerned by the 
long-term effects of their asthma medication the odds 
of poor treatment adherence were 2 (95% CI 1.22–3.27). 
Furthermore, patients who were concerned by the need 
to constantly use their asthma medication seemed to 
have increased odds to have poor treatment adherence, 
but the association was not statistically significant.
In addition, we conducted a correlation analysis 
between the two variables of the BMQ questionnaire 
that were statistically significant predictor of treatment 
adherence. However, no statistically significant 
correlation was observed (r = 0.068; p value 0.199).
Table 1 Baseline characteristics of the study sample
a Standard deviation
Men Women Total
(n = 85) (n = 264) (n = 352)
Age, mean  (SDa) 53.7 (17.4) 58.7 (16.6) 57.5 (16.9)
Education%
 Basic 3.5 7.5 6.5
 Secondary 23.3 27.1 26.1
 Vocational 47.7 28.9 33.5
 Higher 25.6 36.5 33.8
Income%
  < 300 €/month 16.7 25.3 23.2
 300–550 €/month 36.9 48.2 45.5
 550–750 €/month 28.6 18.3 20.8
  > 750 €/month 17.9 8.2 10.6
Asthma medication%
 Glucocorticoids 62.8 63.4 63.3
 Glucocorticoids+beta 2 mimetic 33.7 33.2 33.3
 Poor treatment adherence% 
(MARS-5 item scale)
58.1 68.7 66.1
Table 2 Odds ratio of  socio-demographic and  economic 
factors in regard poor treatment adherence
a Odds ratio
b Confidence interval
MARS 5-item scale
Univariate
ORa (95%  CIb)
Age 0.98 (0.97–1.00)
Female sex 1.58 (0.96–2.60)
Education
 Basic or secondary 1 ref
 Vocational 1.79 (1.03–3.11)
 Higher 1.27 (0.75–2.16)
Income
  < 300 €/month 1 ref
 300–550 €/month 0.86 (0.48–1.55)
 550–750 €/month 0.80 (0.41–1.59)
  > 750 €/month 0.87 (0.38–2.03)
Asthma medication
 Corticosteroids 0.57 (0.35–0.91)
 Corticosteriods+beta 2 mimetic 1.93 (1.18–3.16)
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Discussion
Our study revealed that several beliefs about asthma 
medication were predictors of poor treatment adherence 
in Latvian asthma patients. However, none of the 
indicators of illness perception seemed to be associated 
with suboptimal adherence. Moreover, it is of concern 
that only three out of ten asthma patients in Latvia had 
adequate treatment adherence during the timeframe of 
our study.
Latvia differs from other countries in access to 
medicines. The reimbursement level for asthma 
medication in Latvia is 75% of the pharmacy price and 
therefore patient’s co-payment for a monthly supply of a 
controller medication was 1452 EUR for the most widely 
used medicine at the time of the study. It is a significant 
amount relative to the reported income of our study 
subjects. We may speculate that significant financial 
burden is a factor of low total adherence in our study. 
There have been previous studies that look at this factor. 
A study in US assessed impact of a full reimbursement 
of medication used after myocardial infarction compared 
to a usual reimbursement plan [22]. The results showed 4 
to 6 percentage points higher adherence rate in the full-
coverage group.
The prevalence of poor adherence in Latvian asthma 
patients is higher than reported in previous research 
Table 3 Odds ratio of the association of cognitive and emotional illness indicators and poor treatment adherence
a Odds ratio
b Confidence interval
c Adjusted for age, education and income
MARS 5-item scale
Univariate Mutivariatec
ORa (95%  CIb) OR (95% CI)
How much does your illness affect your life? 0.96 (0.88–1.05) 0.96 (0.88–1.05)
How long do you think your illness will continue? 0.96 (0.87–1.05) 0.98 (0.89–1.08)
How much control do you feel you have over your illness? 0.98 (0.89–1.08) 0.98 (0.88–1.08)
How much do you think your treatment can help your illness? 0.96 (0.86–1.07) 0.96 (0.85–1.07)
How much do you experience symptoms from your illness? 1.01 (0.93–1.10) 1.01 (0.92–1.11)
How concerned are you about your illness? 0.99 (0.93–1.07) 1.01 (0.94–1.09)
How well do you feel you understand your illness? 1.06 (0.98–1.15) 0.98 (0.97–1.15)
How much does your illness affect you emotionally? 1.03 (0.96–1.10) 1.03 (0.96–1.11)
Table 4 Odds ratio of the association between medication beliefs and poor treatment adherence
a Odds ratio
b Confidence interval
c Adjusted for age, education and income
MARS 5-item scale
Univariate Mutivariatec
ORa (95%  CIb) OR (95% CI)
Necessity
 My health is fully dependent on the asthma medication 0.58 (0.36–0.94) 0.61 (0.37–1.01)
 Without asthma medication my life would be impossible 0.64 (0.41–1.01) 0.62 (0.38–1.01)
 Without my asthma medication I would be very ill 0.71 (0.45–1.12) 0.72 (0.44–1.19)
 My future health depends on my asthma medication 0.42 (0.25–0.70) 0.42 (0.24–0.74)
 My controlling asthma medication prevents health deterioration 0.51 (0.28–0.96) 0.61 (0.32–1.17)
Concerns
 I am concerned by the need to constantly use my asthma medication 1.69 (1.07–2.68) 1.59 (0.98–2.57)
 I am sometimes concerned by long term effects of my asthma medication 1.89 (1.19–3.01) 2 (1.22–3.27)
 My asthma medication is incomprehensible to me 1.03 (0.60–1.79) 1.27 (0.70–2.29)
Page 5 of 7Smits et al. Allergy Asthma Clin Immunol           (2020) 16:16  
[6–8] whereas poor adherence to asthma treatment was 
found to be 60% in the USA and was ranging between 
30 and 40% in France, Germany and Italy [6]. Several 
intentional and non-intentional factors have been shown 
to be related to poor treatment adherence [7–9]. Some 
factors are related to the patient, others to the disease, 
treatment or physician–patient relationship [10, 11].
Patients’ medication beliefs may explain a significant 
portion of variation in medication non-adherence 
in asthma patients [12]. Our results in regard beliefs 
about medication and treatment adherence are in 
line with previous findings showing that beliefs about 
the necessity and the concerns about side effects of 
the asthma treatment are well associated with poor 
adherence (Leventhal et  al. 2005); [14–16]. A British 
study in 100 community-based patients showed that 
non-adherent behaviours were associated with doubts 
about the necessity of medication and concerns about 
its potential adverse effects [14]. Furthermore, a cross-
sectional survey among 238 Dutch asthma patients 
also reported that self-reported adherence correlated 
significantly with necessity beliefs and concerns of 
chronic use of inhaled corticosteroids [16]. These beliefs 
and concerns against perceptions of necessity have 
been found to predict adherence to medication not 
only in asthma patients but also in treatment of HIV, 
arthritis and coronary heart disease [15, 16, 23, 24]. In 
addition, current evidence suggests that certain beliefs 
about medicines are more predictive of intentional 
non-adherence than of unintentional non-adherence 
[15]. For instance, in a study among asthma patients in 
New Zealand intentional non-adherence (missing or 
altering doses to suit one’s needs) is associated with 
decision balance, whereas unintentional non-adherence 
(forgetting to take medication) is less strongly associated 
with decision balance and is more strongly associated 
with demographics, in particular age [18].
Patients often make treatment choices according to 
their own understanding and beliefs about the illness 
and treatment. Patients’ adherence to medication is 
particularly influenced by the way in which they evaluate 
their personal need for medication relative to their 
concerns about potential negative effects of taking it. Our 
finding that using fixed-dose combination medications 
containing a corticosteroid and a beta 2 mimetic 
increased the odds of poor treatment adherence might 
seem a paradoxical result since fixed dose combination 
medicines of inhaled corticosteroid and bet 2 mimetic 
offer treatment effect that a patient can feel, whereas 
effects of plain corticosteroid a patient would not usually 
feel as it will reduce number of disease exacerbations 
over time. However, we may speculate that the symptom 
relieving effect of the beta 2 mimetic component of the 
medicine is indeed causing non-adherent behaviour. 
Patients would feel their symptom relief brought by the 
beta 2 mimetic component of their medicine and that 
would shift the necessity-concern balance in the patient’s 
perception. They would decide that their disease is not 
that severe anymore and the resulting action would be 
taking less medicine.
National Institute of Clinical Excellence (NICE) 
guidance recommends addressing any beliefs and 
concerns that patients have that result in reduced 
adherence by uncovering individual’s perceptions of 
their medication during the consultation [25]. BMQ is a 
useful tool to assess medication beliefs and concerns and 
we recommend using at least some questions of BMQ 
routinely if not all of the questionnaire in the clinical 
practice.
The self-regulatory model was developed in order to 
explain illness-related behaviour, including adherence 
to treatment recommendations within the field of non-
communicable diseases [13]. According to that model 
adherence to treatment consists of several components 
that the patient can adopt to cope with their disease. 
Only a few studies have assessed the association between 
illness perception and treatment adherence in asthma 
patients [14, 26]. In contrast to our study, non-adherent 
behaviours were associated with more negative perceived 
consequences of illness in a British study conducted 
among 100 asthma patients [14]. Furthermore, in a 
large Polish survey of 3618 asthma patients, illness 
perception, younger age, disease duration and severity 
were predictors of adherence to treatment with 
fluticasone propionate and formoterol fumarate [26]. It 
has also been suggested that interventions focusing on 
illness perception helped to support chronic obstructive 
pulmonary disease patients in their disease management 
and to improve health-related quality of life [27]. More 
evidence is needed to show whether the same principle 
applies for asthma patients.
Naturally, several limitations may be considered. 
Asthma medication adherence was measured by a 
self-report questionnaire not previously validated in 
the Latvian population. Self-reported measurements 
of medication adherence may not be that precise and 
are subject to self-presentational and recall biases. 
However, MARS is a validated questionnaire that has 
shown to have good internal, construct, and criterion 
validity, including correlations with objective measures 
of adherence (electronic monitoring and pharmacy 
dispensing data) [6, 17]. In addition, as this study is 
cross-sectional in design, no conclusions about an 
association between cause and effect can be taken. Even 
though the patients of this study were recruited from 
the main towns and the capital city where the majority 
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of the Latvian population live, it seems that this could 
over-represent urban populations and underrepresent 
rural populations and the results cannot be generalized 
to the overall population of Latvian asthma patients.
Finally, the study addresses medication adherence 
related to frequency of medication use as per doctors’ 
prescription but does not address medication non 
adherence due to incorrect inhaler technique which is 
another important factor for receiving the appropriate 
dose of medicine.
Conclusion
In conclusion, screening of asthma patients to assess 
their beliefs about their asthma medication may help 
to identify those ones to benefit from interventions 
targeting their concerns in order to improve treatment 
adherence. Many of the common beliefs of the Latvian 
asthma patients could be modified by educational 
interventions performed within the primary health-
care system. This may have the potential to significantly 
reduce the economic burden related to poor asthma 
control and improve the quality of life of asthma 
patients in a cost-effective way.
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